Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H23N3O |
| Molecular Weight | 297.3947 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](C[C@@](C(N)=O)(C1=CC=CC=C1)C2=NC=CC=C2)N(C)C
InChI
InChIKey=BWNLUIXQIHPUGO-RDTXWAMCSA-N
InChI=1S/C18H23N3O/c1-14(21(2)3)13-18(17(19)22,15-9-5-4-6-10-15)16-11-7-8-12-20-16/h4-12,14H,13H2,1-3H3,(H2,19,22)/t14-,18-/m1/s1
| Molecular Formula | C18H23N3O |
| Molecular Weight | 297.3947 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Vamicamide [FK 176, Urocut®] is an antagonist of muscarinic receptors, developed by Japanese company Fujisawa for the treatment of urinary incontinence. Fujisawa has withdrawn its application to market vamicamide because confirmatory studies conducted with the drug since the application have failed to show any superiority for vamicamide over an active control medication.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:36 GMT 2025
by
admin
on
Mon Mar 31 18:14:36 GMT 2025
|
| Record UNII |
RU10K34QRU
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6743
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
RU10K34QRU
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
100000079051
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
SUB00020MIG
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
C083702
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
C75289
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
132373-81-0
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
CHEMBL28979
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
m519
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID201336894
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY | |||
|
65967
Created by
admin on Mon Mar 31 18:14:36 GMT 2025 , Edited by admin on Mon Mar 31 18:14:36 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
